cilostazol has been researched along with Peripheral Vascular Diseases in 47 studies
Peripheral Vascular Diseases: Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 9.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "This study evaluated the effects of cilostazol on walking distances in patients with intermittent claudication (IC) caused by peripheral arterial occlusive disease." | 9.08 | Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. ( Cutler, B; Davidson, M; Forbes, WP; Heckman, J; Herd, JA; Isaacsohn, JL; Money, SR, 1998) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 8.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 8.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| "To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 8.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
| " The apparent elimination half-life of cilostazol (approximately 11 hours) was similar after a single dose or after multiple doses, with steady state being reached within 4 days." | 6.69 | Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. ( Bramer, SL; Forbes, WP; Mallikaarjun, S, 1999) |
| "Cilostazol also has antiplatelet, antithrombotic, and vasodilatory activity, as well as a positive effect on serum lipids." | 6.41 | Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. ( Smith, JA, 2002) |
| "Cilostazol, a phosphodiesterase III inhibitor, is indicated to treat the symptoms of intermittent claudication and increase walking distance in patients with peripheral arterial disease (PAD)." | 5.13 | Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects). ( Brass, EP; Hiatt, WR; Money, SR, 2008) |
| "To determine the effect of cilostazol on initial and absolute claudication distances, mortality and vascular events in patients with stable intermittent claudication." | 5.12 | Cilostazol for intermittent claudication. ( Brown, T; Cleanthis, M; Forster, RB; Mikhailidis, DP; Stansby, G; Stewart, M, 2021) |
| "This study evaluated the effects of cilostazol on walking distances in patients with intermittent claudication (IC) caused by peripheral arterial occlusive disease." | 5.08 | Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. ( Cutler, B; Davidson, M; Forbes, WP; Heckman, J; Herd, JA; Isaacsohn, JL; Money, SR, 1998) |
| "To determine the effect of cilostazol (an antiplatelet treatment) on improving initial and absolute claudication distances, and in reducing mortality and vascular events in patients with stable intermittent claudication." | 4.90 | Cilostazol for intermittent claudication. ( Bedenis, R; Cleanthis, M; Mikhailidis, DP; Robless, P; Stansby, G; Stewart, M, 2014) |
| "A systematic review and network meta-analysis was undertaken to consider the evidence for the efficacy and tolerability of placebo, cilostazol, naftidrofuryl oxalate and pentoxifylline in patients with intermittent claudication due to peripheral arterial disease (PAD)." | 4.88 | Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. ( Harnan, S; Meng, Y; Michaels, J; Simpson, E; Squires, H; Stansby, G; Stevens, JW; Thomas, S, 2012) |
| " Randomised placebo controlled trials have shown that the phosphodiesterase III inhibitor cilostazol 100mg bid improves pain-free and maximum walking distance, as well as quality of life, in a range of patients with intermittent claudication in whom there is no evidence of tissue necrosis or rest pain." | 4.84 | Medical therapy for intermittent claudication. ( Donnelly, R; Rowlands, TE, 2007) |
| "To assess whether cilostazol, a phosphodiesterase III inhibitor, improves treadmill and community-based walking ability and health-related quality of life (HQL) in patients with intermittent claudication resulting from peripheral arterial disease (PAD)." | 4.81 | Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. ( Forbes, WP; Heckman, J; Hiatt, WR; McCarthy, WJ; Regensteiner, JG; Ware, JE; Zhang, P, 2002) |
| " For this study, 20 PAD patients were assigned to take either pentoxifylline (n=11) or cilostazol (n=9), the two FDA-approved pharmacological therapies used to treat intermittent claudication symptoms." | 3.76 | Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes. ( Huisinga, JM; Johanning, JM; Pipinos, II; Stergiou, N, 2010) |
| "The cilostazol treatment group demonstrated significant improvements in the Short Form-36 (physical functioning, physical component score), Walking Impairment (distance and speed), and Vascular Quality of Life (pain) indices at 6 and 24 weeks." | 2.74 | The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. ( Badger, SA; Lee, B; O'Donnell, ME; Sharif, MA; Soong, CV; Young, IS, 2009) |
| "Cilostazol is an anti-thrombotic and vasodilating agent, reported to have both anti-thrombotic and cerebral vasodilating effects." | 2.71 | Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease. ( Hamazaki, T; Johkaji, H; Kobayashi, M; Minami, S; Nakamura, N; Okomura, K; Osawa, H; Satoh, A; Sawazaki, S; Urakaze, M; Yamabe, H; Yamazaki, K, 2003) |
| " The apparent elimination half-life of cilostazol (approximately 11 hours) was similar after a single dose or after multiple doses, with steady state being reached within 4 days." | 2.69 | Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. ( Bramer, SL; Forbes, WP; Mallikaarjun, S, 1999) |
| "Cilostazol is a phosphodiesterase inhibitor licensed for treating patients suffering from intermittent claudication." | 2.45 | A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. ( Dindyal, S; Kyriakides, C, 2009) |
| "Food and Drug Administration for the treatment of intermittent claudication, several supplements and investigational agents have been evaluated." | 2.45 | Pharmacologic therapy for intermittent claudication. ( Dobesh, PP; Persson, EL; Stacy, ZA, 2009) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2007) |
| "Cilostazol is a potent type III phosphodiesterase inhibitor with pharmacological effects that include vasodilatation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.44 | Cilostazol in the management of vascular disease. ( Dalainas, I, 2007) |
| "Cilostazol has been shown to be of benefit in improving walking distance in people with IC." | 2.44 | Cilostazol for peripheral arterial disease. ( Mikhailidis, DP; Robless, P; Stansby, GP, 2008) |
| "Cilostazol is a phosphodiesterase III inhibitor with pharmacological effects that include vasodilation, inhibition of platelet activation and aggregation, inhibition of thrombosis, increased blood flow to the limbs, improvement in serum lipids with lowering of triglycerides and elevation of high density lipoprotein cholesterol, and inhibition of vascular smooth muscle cell growth." | 2.43 | The vascular effects of cilostazol. ( Weintraub, WS, 2006) |
| "Cilostazol also has antiplatelet, antithrombotic, and vasodilatory activity, as well as a positive effect on serum lipids." | 2.41 | Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication. ( Smith, JA, 2002) |
| "Intermittent claudication is a form of exercise intolerance characterized by muscle pain during walking in patients with peripheral artery disease (PAD)." | 1.40 | Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice. ( Alcantara, R; Baltgalvis, KA; Claypool, MD; Friera, AM; Godinez, G; Goff, D; Gururaja, T; Hansen, D; Hitoshi, Y; Jenkins, Y; Kinsella, TM; Lang, W; Lau, D; Li, W; Li, Y; Markovtsov, V; McCaughey, K; McLaughlin, J; Nguyen, H; Pan, A; Park, G; Payan, DG; Shaw, SJ; Singh, BK; Singh, R; Smith, IJ; Sun, TQ; Uy, G; White, K, 2014) |
| "Effects of cilostazol on preventing restenosis after PTA in these patients were investigated." | 1.35 | Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease. ( Aoyama, T; Ishii, H; Kumada, Y; Maruyama, S; Matsubara, T; Matsuo, S; Murohara, T; Takahashi, H; Toriyama, T; Yamada, S; Yasuda, Y; Yuzawa, Y, 2008) |
| "Cilostazol was then added in a cumulative manner (680-2,720 microg/L), and the tension generated was recorded." | 1.33 | Effects of cilostazol on human venous smooth muscle. ( Becker, RW; Kline, RA; Lusis, E; Sohn, RL, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (6.38) | 18.2507 |
| 2000's | 32 (68.09) | 29.6817 |
| 2010's | 11 (23.40) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, T | 1 |
| Forster, RB | 1 |
| Cleanthis, M | 2 |
| Mikhailidis, DP | 4 |
| Stansby, G | 3 |
| Stewart, M | 2 |
| Baltgalvis, KA | 1 |
| White, K | 1 |
| Li, W | 1 |
| Claypool, MD | 1 |
| Lang, W | 1 |
| Alcantara, R | 1 |
| Singh, BK | 1 |
| Friera, AM | 1 |
| McLaughlin, J | 1 |
| Hansen, D | 1 |
| McCaughey, K | 1 |
| Nguyen, H | 1 |
| Smith, IJ | 1 |
| Godinez, G | 1 |
| Shaw, SJ | 1 |
| Goff, D | 1 |
| Singh, R | 1 |
| Markovtsov, V | 1 |
| Sun, TQ | 1 |
| Jenkins, Y | 1 |
| Uy, G | 1 |
| Li, Y | 1 |
| Pan, A | 1 |
| Gururaja, T | 1 |
| Lau, D | 1 |
| Park, G | 1 |
| Hitoshi, Y | 1 |
| Payan, DG | 1 |
| Kinsella, TM | 1 |
| Bedenis, R | 1 |
| Robless, P | 3 |
| Mayer, CA | 1 |
| Murawska, A | 1 |
| Bishop, J | 1 |
| Waits, J | 1 |
| Smith, L | 1 |
| Pearce, L | 1 |
| Ghosh, J | 1 |
| Counsell, A | 1 |
| Serracino-Inglott, F | 1 |
| Dindyal, S | 1 |
| Kyriakides, C | 1 |
| O'Donnell, ME | 1 |
| Badger, SA | 1 |
| Sharif, MA | 1 |
| Young, IS | 1 |
| Lee, B | 1 |
| Soong, CV | 1 |
| Chi, YW | 1 |
| Lavie, CJ | 1 |
| Milani, RV | 1 |
| White, CJ | 1 |
| Dobesh, PP | 1 |
| Stacy, ZA | 1 |
| Persson, EL | 1 |
| Ishii, H | 2 |
| Kumada, Y | 2 |
| Toriyama, T | 2 |
| Aoyama, T | 2 |
| Takahashi, H | 2 |
| Tanaka, M | 1 |
| Kamoi, D | 1 |
| Kawamura, Y | 1 |
| Yamada, S | 2 |
| Hayashi, M | 1 |
| Yasuda, Y | 2 |
| Yuzawa, Y | 2 |
| Maruyama, S | 2 |
| Matsuo, S | 2 |
| Matsubara, T | 2 |
| Murohara, T | 2 |
| Shigematsu, H | 1 |
| Nishibe, T | 1 |
| Obitsu, Y | 1 |
| Matsuzaki, K | 1 |
| Ishida, A | 1 |
| Miyata, T | 1 |
| Shindo, S | 1 |
| Hida, K | 1 |
| Ohta, T | 1 |
| Ando, M | 1 |
| Kawasaki, T | 1 |
| Yasugi, T | 1 |
| Matsumoto, T | 1 |
| Huisinga, JM | 2 |
| Pipinos, II | 2 |
| Johanning, JM | 2 |
| Stergiou, N | 2 |
| Olin, JW | 1 |
| Sealove, BA | 1 |
| Yoshikawa, H | 1 |
| Suzuki, M | 1 |
| Hashimoto, G | 1 |
| Otsuka, T | 1 |
| Sugi, K | 1 |
| Shiohira, S | 1 |
| Yoshida, T | 1 |
| Sugiura, H | 1 |
| Yoshida, S | 1 |
| Mitobe, M | 1 |
| Shimada, K | 1 |
| Ohba, T | 1 |
| Tsuchiya, K | 1 |
| Kabaya, T | 1 |
| Nitta, K | 1 |
| Stevens, JW | 1 |
| Simpson, E | 1 |
| Harnan, S | 1 |
| Squires, H | 1 |
| Meng, Y | 1 |
| Thomas, S | 1 |
| Michaels, J | 1 |
| Hittel, N | 1 |
| Donnelly, R | 2 |
| Grouse, JR | 1 |
| Allan, MC | 1 |
| Elam, MB | 1 |
| Regensteiner, JG | 3 |
| Ware, JE | 1 |
| McCarthy, WJ | 1 |
| Zhang, P | 1 |
| Forbes, WP | 3 |
| Heckman, J | 2 |
| Hiatt, WR | 4 |
| Nakamura, N | 1 |
| Hamazaki, T | 1 |
| Johkaji, H | 1 |
| Minami, S | 1 |
| Yamazaki, K | 1 |
| Satoh, A | 1 |
| Sawazaki, S | 1 |
| Urakaze, M | 1 |
| Kobayashi, M | 1 |
| Osawa, H | 1 |
| Yamabe, H | 1 |
| Okomura, K | 1 |
| Bachoo, P | 3 |
| Becker, RW | 1 |
| Lusis, E | 1 |
| Sohn, RL | 1 |
| Kline, RA | 1 |
| Weintraub, WS | 1 |
| Kim, DH | 1 |
| Finucane, TE | 1 |
| Cassar, K | 1 |
| Stewart, KJ | 1 |
| Rao, AK | 1 |
| Vaidyula, VR | 1 |
| Bagga, S | 1 |
| Jalagadugula, G | 1 |
| Gaughan, J | 1 |
| Wilhite, DB | 1 |
| Comerota, AJ | 1 |
| Stansby, GP | 2 |
| Dalainas, I | 1 |
| Rowlands, TE | 1 |
| Money, SR | 2 |
| Brass, EP | 1 |
| Kumar, M | 1 |
| Bhattacharya, V | 1 |
| Lipsitz, EC | 1 |
| Kim, S | 1 |
| Falconer, TM | 1 |
| Eikelboom, JW | 1 |
| Hankey, GJ | 1 |
| Norman, PE | 1 |
| Herd, JA | 1 |
| Isaacsohn, JL | 1 |
| Davidson, M | 1 |
| Cutler, B | 1 |
| Bramer, SL | 1 |
| Mallikaarjun, S | 1 |
| Nehler, MR | 1 |
| Smith, JA | 1 |
| Uchikawa, T | 1 |
| Murakami, T | 1 |
| Furukawa, H | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Effect of Exercise and/or Liraglutide on Vascular Dysfunction and Insulin Sensitivity in Type 2 Diabetes ( ZQL007)[NCT03883412] | Phase 4 | 60 participants (Anticipated) | Interventional | 2019-02-28 | Recruiting | ||
| Evaluation of Cilostazol in Combination With L-Carnitine in Subjects With Intermittent Claudication[NCT00822172] | Phase 4 | 164 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.065 |
| Cilostazol + Placebo | 0.896 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. The time during the conduct of the exercise treadmill test at which the subject first reported claudication symptoms is referred to as the claudication onset time (COT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 1.001 |
| Cilostazol + Placebo | 0.815 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.241 |
| Cilostazol + Placebo | 0.134 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.267 |
| Cilostazol + Placebo | 0.145 |
Subjects were asked to complete a standardized exercise treadmill test using a modified Gardner protocol. Subjects walked on the treadmill until they were physically unable to walk further either as a result of their peripheral artery disease (PAD) symptoms or other non-PAD symptoms. This maximum time walked is referred to as the peak walking time (PWT) and reported in minutes/seconds. The exercise treadmill test was conducted at Screening, Baseline, Day 90, and Day 180 visits. The log transformation is used to make highly skewed distributions less skewed. (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | Log Minutes (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 0.166 |
| Cilostazol + Placebo | 0.139 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 180
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 13.20 |
| Cilostazol + Placebo | 6.57 |
Subjects completed the Walking Impairment Questionnaire (WIQ) whereby they were asked about their maximal walking distance before having to rest as a result of claudication symptoms associated with their peripheral artery disease (PAD). The WIQ was administered at the Baseline, Day 90, and Day 180 visits. On the WIQ subjects were asked a series of questions related to their degree of physical difficulty that best described how hard it was for the subject to walk on level ground without stopping to rest. The questions began by asking the degree of difficulty walking around indoors, then 50 feet, 150 feet, 300 feet, 600 feet, 900 feet, and lastly 1500 feet. The responses range from None (best outcome) to Slight, then Some, then Much, then lastly Unable (worst outcome). The walking distance score was calculated from the 7 questions in the section by way of a weighted sum. A score of 100 indicated no walking impairment. A score of 0 corresponded to the highest degree of walking impairment (NCT00822172)
Timeframe: Baseline, Day 90
| Intervention | score on a scale (Mean) |
|---|---|
| Cilostazol + L-Carnitine | 12.98 |
| Cilostazol + Placebo | 10.01 |
26 reviews available for cilostazol and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Cilostazol for intermittent claudication.
Topics: Aged; Bias; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pento | 2021 |
Cilostazol for intermittent claudication.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Pentoxifyll | 2014 |
Peripheral Vascular Disease: Treatment in Older Adults.
Topics: Adult; Aged; Aged, 80 and over; Cilostazol; Exercise Therapy; Health Services for the Aged; Humans; | 2017 |
Cilostazol and peripheral arterial disease.
Topics: Angioplasty, Balloon, Coronary; Cell Proliferation; Cilostazol; Exercise; Humans; Lipids; Peripheral | 2008 |
A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy.
Topics: Angioplasty; Arterial Occlusive Diseases; Cilostazol; Clinical Trials as Topic; Coronary Restenosis; | 2009 |
Safety and efficacy of cilostazol in the management of intermittent claudication.
Topics: Cardiovascular Agents; Cilostazol; Exercise Tolerance; Humans; Intermittent Claudication; Peripheral | 2008 |
Pharmacologic therapy for intermittent claudication.
Topics: Cilostazol; Clinical Trials as Topic; Dietary Supplements; Drugs, Investigational; Exercise Therapy; | 2009 |
Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Nafronyl; Pain; Pentoxifylline; Peripheral Vascular D | 2012 |
Treating peripheral arterial disease in patients with diabetes.
Topics: Cilostazol; Diabetic Angiopathies; Disease Progression; Humans; Peripheral Vascular Diseases; Phosph | 2002 |
Clinical manifestation of atherosclerotic peripheral arterial disease and the role of cilostazol in treatment of intermittent claudication.
Topics: Arteriosclerosis; Cholesterol, HDL; Cilostazol; Clinical Trials as Topic; Humans; Hypolipidemic Agen | 2002 |
Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.
Topics: Aged; Cilostazol; Exercise Test; Humans; Intermittent Claudication; Intracranial Arterial Diseases; | 2002 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Intermittent Claudication; Pentoxifylline; Perip | 2003 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Exercise; Humans; Pentoxifylline; Peripheral Vascular Diseases; Pl | 2004 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Coronary Artery Bypass; Exercise; Humans; Pentoxifylline; Peripher | 2004 |
The vascular effects of cilostazol.
Topics: Animals; Cell Proliferation; Cilostazol; Coronary Restenosis; Endothelium, Vascular; Humans; Lipids; | 2006 |
Peripheral arterial disease.
Topics: Angioplasty, Balloon; Cilostazol; Coronary Artery Bypass; Exercise; Humans; Hydroxymethylglutaryl-Co | 2006 |
Established and evolving medical therapies for claudication in patients with peripheral arterial disease.
Topics: Ankle; Arterial Occlusive Diseases; Blood Pressure; Brachial Artery; Cilostazol; Exercise Test; Exer | 2006 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2007 |
Cilostazol in the management of vascular disease.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; | 2007 |
Medical therapy for intermittent claudication.
Topics: Aged; Angiogenic Proteins; Animals; Cardiovascular Agents; Cilostazol; Collateral Circulation; Femal | 2007 |
Cilostazol: a new drug in the treatment intermittent claudication.
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Vascular Diseases; Phosphodiesterase 3 Inh | 2007 |
Cilostazol for peripheral arterial disease.
Topics: Aged; Cilostazol; Humans; Intermittent Claudication; Middle Aged; Myocardial Infarction; Peripheral | 2008 |
Management of peripheral arterial disease in the elderly: focus on cilostazol.
Topics: Aged; Cilostazol; Diabetic Angiopathies; Dose-Response Relationship, Drug; Dyslipidemias; Humans; Hy | 2008 |
Peripheral arterial disease.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cilostazol; Diabetes Complications; Diabetes Mellitus; Dis | 2001 |
Current medical therapies for patients with peripheral arterial disease: a critical review.
Topics: Angiotensin-Converting Enzyme Inhibitors; Arteriosclerosis; Cardiovascular Diseases; Cilostazol; Dia | 2002 |
Measuring treatment effects of cilostazol on clinical trial endpoints in patients with intermittent claudication.
Topics: Aged; Cilostazol; Female; Humans; Intermittent Claudication; Male; Middle Aged; Peripheral Vascular | 2002 |
7 trials available for cilostazol and Peripheral Vascular Diseases
| Article | Year |
|---|---|
The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.
Topics: Adult; Aged; Aged, 80 and over; Ankle; Aorta; Biomarkers; Blood Pressure; Brachial Artery; Cardiovas | 2009 |
Effects of cilostazol on serum lipid concentrations and plasma fatty acid composition in type 2 diabetic patients with peripheral vascular disease.
Topics: Aged; Apolipoproteins; Arteriosclerosis; Blood Glucose; Cilostazol; Diabetes Mellitus, Type 2; Fasti | 2003 |
Effect of antiplatelet agents clopidogrel, aspirin, and cilostazol on circulating tissue factor procoagulant activity in patients with peripheral arterial disease.
Topics: Aged; Aged, 80 and over; Antithrombin III; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand | 2006 |
Long-term safety of cilostazol in patients with peripheral artery disease: the CASTLE study (Cilostazol: A Study in Long-term Effects).
Topics: Aged; Cardiovascular Diseases; Cilostazol; Double-Blind Method; Female; Hemorrhage; Humans; Intermit | 2008 |
Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
Topics: Cilostazol; Double-Blind Method; Exercise Test; Exercise Tolerance; Female; Humans; Intermittent Cla | 1998 |
Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
Topics: Administration, Oral; Analysis of Variance; Area Under Curve; Cilostazol; Cross-Over Studies; Drug A | 1999 |
Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus.
Topics: Adult; Aged; Arteriosclerosis Obliterans; Cilostazol; Diabetic Angiopathies; Female; Fingers; Humans | 1992 |
14 other studies available for cilostazol and Peripheral Vascular Diseases
| Article | Year |
|---|---|
Exercise performance and peripheral vascular insufficiency improve with AMPK activation in high-fat diet-fed mice.
Topics: Aging; AMP-Activated Protein Kinases; Animals; Apolipoproteins E; Arginine; Cilostazol; Diet, High-F | 2014 |
Effects of oral cilostazol 100 mg BID on long-term patency after percutaneous transluminal angioplasty in patients with femoropopliteal disease undergoing hemodialysis: a retrospective chart review in Japanese patients.
Topics: Aged; Angioplasty, Balloon; Asian People; Cilostazol; Female; Femoral Artery; Follow-Up Studies; Hum | 2010 |
Three-year cardiovascular events and disease progress in patients with peripheral arterial disease: results from the Japan Medication Therapy for Peripheral Arterial Disease (J-METHOD).
Topics: Adult; Aged; Aged, 80 and over; Ankle Brachial Index; Aspirin; Cardiovascular Agents; Cardiovascular | 2010 |
The effect of pharmacological treatment on gait biomechanics in peripheral arterial disease patients.
Topics: Aged; Biomechanical Phenomena; Cardiovascular Agents; Case-Control Studies; Cilostazol; Dyskinesias; | 2010 |
Peripheral artery disease: current insight into the disease and its diagnosis and management.
Topics: Ankle Brachial Index; Cardiovascular Diseases; Cilostazol; Diagnosis, Differential; Disease Progress | 2010 |
Treatment with pharmacological agents in peripheral arterial disease patients does not result in biomechanical gait changes.
Topics: Aged; Analysis of Variance; Biomechanical Phenomena; Cilostazol; Female; Gait; Humans; Imaging, Thre | 2010 |
Impact of cilostazol on left ventricular geometry and function: assessment by tissue Doppler imaging and two-dimensional speckle-tracking echocardiography.
Topics: Administration, Oral; Aged; Blood Pressure; Cerebrovascular Disorders; Cilostazol; Comorbidity; Echo | 2011 |
Effect of the antiplatelet agent cilostazol on endovascular inflammatory biochemical parameters and the clinical symptoms of peripheral artery disease and restless legs syndrome in hemodialysis patients.
Topics: Aged; Biomarkers; Case-Control Studies; Cilostazol; Female; Humans; Inflammation Mediators; Japan; L | 2011 |
Effects of cilostazol on human venous smooth muscle.
Topics: Cilostazol; Diabetes Mellitus; Dose-Response Relationship, Drug; Humans; Hypercholesterolemia; Hyper | 2005 |
Exercise and peripheral arterial disease.
Topics: Cilostazol; Exercise Therapy; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular | 2006 |
Medical management of peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Peripheral Vascular Diseases; Tetrazoles; Vasodilator | 2006 |
Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.
Topics: Aged; Angioplasty, Balloon; Cilostazol; Constriction, Pathologic; Female; Humans; Kaplan-Meier Estim | 2008 |
Antithrombotic therapy in peripheral arterial disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie | 2008 |
A new treatment for peripheral arterial disease.
Topics: Cilostazol; Humans; Intermittent Claudication; Pentoxifylline; Peripheral Vascular Diseases; Platele | 2001 |